Search

Displaying results 4341 - 4350 of 5504 in total
  1. Drug

    Cythioate

    go.drugbank.com/drugs/DB11392
    ExperimentalVet approved

    It is mainly used in veterinary as a treatment for fleas.

  2. Drug

    NOP-1A

    go.drugbank.com/drugs/DB15208
    Investigational

    NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).

  3. Drug

    AEM-28

    go.drugbank.com/drugs/DB17642
    Investigational

    AEM-28 is a 28 amino acid mimetic of apolipoprotein E being investigated for lipid disorders, such as homozygous familial hypercholesterolemia. It possesses anti-inflammatory properties.[A258764]

  4. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    It is being investigated for the treatment of hyperoxaluria.[A258823]

  5. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  6. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    It is under investigation for the treatment of growth hormone deficiency.

  7. Drug

    Socazolimab

    go.drugbank.com/drugs/DB18845
    Investigational

    Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).

  8. Drug

    Elzovantinib

    go.drugbank.com/drugs/DB18918
    Investigational

    Elzovantinib is under investigation in clinical trial NCT03993873 (Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET).

  9. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

  10. Drug

    RUS 3108

    go.drugbank.com/drugs/DB05911
    Experimental

    RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories. The drug’s Phase I clinical trials have been initiated in Europe ...